Way i see it was way back when, the market didn't know how to evaluate the stock, and even though much has changed since in terms of shares on issue, patent life, and progress in the lab, the market still doesn't know how to evaluate the stock.
And that's not to blame the market - there's not really any tangible handle for it to grab yet. There's only been an indirect hint thus far (Tacere / Pfizer HCV deal).
Calimmune's pending HIV trial will take viral delivered shRNA (aka ddRNAi aka expressed RNAi) now to 3 trials in the clinic - the others being CoH HIV and Gradalis's solid tumor PII 'Fang' trial.
There's obviously plenty of stuff happening in the labs, and now the clinical work is gaining momentum. Pfizer's TT033 might be in clinic before the year is out too - which would take ddRNAi to 4 in the clinic.
Good thing is we only need to kick one of these big goals, and benitec's business is only about kicking big ones.
BLT Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
